Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8542190 | 0.98 | LRRK2 (0.49) | LRRK2JAK2 | |
| SCHEMBL4535369 | 0.80 | LRRK2 (0.51) | LRRK2JAK2 | |
| SCHEMBL15946660 | 0.78 | LRRK2 (0.64) | LRRK2JAK2 | |
| SCHEMBL12586215 | 0.77 | NUDT1 (0.35) | LRRK2JAK2 | |
| SCHEMBL14994344 | 0.77 | BCL6 (0.56) | LRRK2JAK2 | |
| SCHEMBL13057442 | 0.75 | GABBR2 (0.45) | JAK2 | |
| SCHEMBL12094542 | 0.74 | ALDH1A1 (0.41) | JAK2 | |
| SCHEMBL18567341 | 0.74 | CYP1A2 (0.30) | — | |
| SCHEMBL12876515 | 0.74 | LMNA (0.36) | — | |
| SCHEMBL22911857 | 0.74 | LRRK2 (0.50) | LRRK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-0873317-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997013759-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | LRRK2 368/4885JAK2 426/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | LRRK2 1767/4885JAK2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.